GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accuray Inc (NAS:ARAY) » Definitions » Tax Expense

Accuray (Accuray) Tax Expense : $3.8 Mil (TTM As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Accuray Tax Expense?

Accuray's tax expense for the months ended in Mar. 2024 was $0.4 Mil. Its tax expense for the trailing twelve months (TTM) ended in Mar. 2024 was $3.8 Mil.


Accuray Tax Expense Historical Data

The historical data trend for Accuray's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accuray Tax Expense Chart

Accuray Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.09 1.86 1.75 3.35 2.49

Accuray Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.58 1.93 0.88 0.44

Accuray Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accuray  (NAS:ARAY) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Accuray Tax Expense Related Terms

Thank you for viewing the detailed overview of Accuray's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Accuray (Accuray) Business Description

Traded in Other Exchanges
Address
1240 Deming Way, Madison, WI, USA, 53717
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
Executives
Gina Corradetti officer: VP, Corporate Controller 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Ali Pervaiz officer: SVP Chief Financial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Jesse Chew officer: SVP and General Counsel 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Sandeep Chalke officer: SVP, Chief Commercial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Suzanne C Winter officer: SVP & Chief Commercial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Patrick Spine officer: SVP, Chief Admin Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Michael Hoge officer: Senior VP Global Operations 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Robert Kill director VIRTUAL RADIOLOGIC CORPORATION, 5995 OPUS PARKWAY, SUITE 200, MINNETONKA MN 55343
Brandon W Green officer: Chief Financial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Franco N Palomba officer: VP, Chief Accounting Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Byron C Scott director 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Joshua Levine officer: President & CEO 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Mika Nishimura director 471 EL CAMINO REAL, SANTA CLARA CA 95050
Joseph E Whitters director
Shigeyuki Hamamatsu officer: VP, Finance and CAO 1875 CHARLESTON ROAD, MOUNTAIN VIEW CA 94043